Table 1. Demographic and clinical characteristics of the study participants.
| Total (n = 1525) | Impaired (n = 799) | Unimpaired (n = 726) | P | |
|---|---|---|---|---|
| Age [years, mean (SD)] | 43.2 (8.5) | 43.5 (8.2) | 42.8 (8.7) | 0.11 |
| Education [years, mean (SD)] | 12.5 (2.5) | 12.5 (2.5) | 12.5 (2.6) | 0.87 |
| Male [n (%)] | 1173 (77) | 601 (75) | 572 (79) | 0.10 |
| White [n (%)] | 602 (39) | 321 (40) | 281 (39) | 0.41 |
| Current CD4 cell count [cells/μl, median (IQR)] | 420 (262–603) | 409 (251–607) | 428 (267–602) | 0.40 |
| CD4 nadir [cells/μl, median (IQR)] | 172 (48–297) | 155 (37–277) | 187 (58–324) | 0.002 |
| Time since CD4 nadir [years, median (IQR)] | 2.2 (0.5–6.4) | 2.2 (0.6–6.4) | 2.3 (0.5–6.4) | 0.97 |
| Plasma VL <50copies/ml [n (%)] | 895 (59) | 460 (58) | 435 (61) | 0.42 |
| Estimated duration HIV [months, median (IQR)] | 120 (53–178) | 121 (54–177) | 120 (53–178) | 0.76 |
| CART status [n (%)] | 0.007 | |||
| Naive | 229 (15) | 106 (13) | 123 (17) | |
| Past CART | 216 (14) | 97 (12) | 119 (16) | |
| Current CART | 1080 (71) | 595 (75) | 484 (67) | |
| HCV-positive | 396 (26) | 208 (26) | 188 (26) | 0.95 |
CART, combination antiretroviral therapy;HCV, hepatitis C virus;IQR, interquartile range;VL, viral load.